金陵药业股份有限公司 2016 年第三季度报告正文 证券代码：000919 证券简称：金陵药业 公告编号：2016-027 金陵药业股份有限公司 2016 年第三季度报告正文 1 金陵药业股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈志龙、主管会计工作负责人李春敏及会计机构负责人(会计主 管人员)汪 洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,895,242,497.00 | | 3,850,257,581.02 | 1 ...

2016 年半年度报告 2016-024 2016 年 08 月 金陵药业股份有限公司 2016 年半年度报告全文 金陵药业股份有限公司 1 金陵药业股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人沈志龙、主管会计工作负责人李春敏及会计机构负责人(会计主 管人员)汪洋声明：保证本半年度报告中财务报告的真实、准确、完整。 本公司 2016 年半年度报告涉及的公司未来计划、发展战略等前瞻性描述不 构成公司对投资者的实质承诺，敬请投资者注意投资风险。 2 | 目录 | | --- | | 2016 | 半年度报告 1 | | --- | --- | | 第一节 | 重要提示、目录和释义 2 | | 第二节 | 公司简介 5 | | 第三节 | 会计数据和财务指标摘要 7 | | 第四节 | 董事会报告 9 | | 第五节 | 重要事 ...

金陵药业股份有限公司 2016 年第一季度报告正文 证券代码：000919 证券简称：金陵药业 公告编号：2016-011 金陵药业股份有限公司 2016 年第一季度报告正文 1 金陵药业股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈志龙、主管会计工作负责人李春敏及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 870,225,899.02 | 712,972,532.63 | 22.06% | | 归属于上市公 ...

Financial Performance - The company's operating revenue for 2015 was CNY 3,221,375,385.30, representing a 16.21% increase compared to CNY 2,771,942,286.51 in 2014[15] - The net profit attributable to shareholders for 2015 was CNY 208,109,272.30, which is a 5.54% increase from CNY 197,184,453.90 in 2014[15] - The net profit after deducting non-recurring gains and losses was CNY 173,828,207.51, reflecting a 1.70% increase from CNY 170,914,204.32 in 2014[15] - The basic earnings per share for 2015 was CNY 0.4129, up 5.55% from CNY 0.3912 in 2014[15] - The net profit attributable to the parent company was CNY 208,109,300, reflecting a stable performance amid challenging market conditions[32] - The company reported a net profit of 121,615,527.76 CNY for 2015, with a distributable profit of 656,301,533.84 CNY at year-end[90] - The company reported a significant increase of 77.52% in cash inflows from investment activities, primarily due to increased cash recovered from securities investments[56] - The investment income for the year was CNY 79,024,480.61, representing a 24.01% increase compared to the previous year[59] Cash Flow and Assets - The net cash flow from operating activities decreased by 29.16% to CNY 212,449,641.49 from CNY 299,891,714.98 in 2014[15] - The company's cash and cash equivalents decreased by 83.38% to CNY -38,743,881.30, primarily due to increased cash receipts from sales and investment recoveries[36] - The total cash and cash equivalents decreased by 38,743,881.30 CNY, a significant improvement compared to a decrease of 233,178,067.76 CNY in the previous year[57] - Cash and cash equivalents decreased to CNY 698,177,060, representing 18.13% of total assets, down from 20.07% the previous year[61] - The company's total assets decreased slightly to ¥2,100,687,808.91 from ¥2,111,315,808.21 at the beginning of the period[196] Investments and R&D - Research and development investment rose to CNY 41,042,760.11, marking a 2.26% increase from the previous year[36] - The company is actively involved in the development of new medical services and products, including traditional Chinese medicine and modern pharmaceuticals[24] - The company has over 10 ongoing research projects, with three projects currently in the clinical review stage[54] - The company is actively pursuing technological innovation and product development, evidenced by the recognition of its "Guiguang brand Maixue Ning injection" as a new technology product by the China Association of Traditional Chinese Medicine[35] Market and Industry Context - The pharmaceutical industry in China saw a revenue growth of 9.1% in 2015, with total profits increasing by 12.9%, highlighting a robust market environment[24] - The demand for healthcare remains strong in China, supported by an aging population and changing disease patterns, indicating long-term stable growth for the pharmaceutical market[76] - The pharmaceutical industry is facing stricter regulatory environments, increasing operational costs due to higher production standards and stringent drug reviews[76] Corporate Governance and Management - The company has established a governance structure to protect the rights of shareholders and creditors[124] - The company has a strong management team, including CEO Li Chunmin, who has been with the company since June 2011, focusing on strategic growth and financial oversight[149] - The company has a commitment to governance, as evidenced by the appointment of independent directors and the establishment of a supervisory board to oversee management activities[146] - The company has maintained a focus on investment and planning, with members like Xiao Ling and Chen Jinbao involved in strategic investment roles since 2015[153] Shareholder Information - The company plans to distribute a cash dividend of CNY 1.7 per 10 shares, based on a total of 504,000,000 shares[5] - The company distributed cash dividends of 85,680,000.00 CNY, representing 41.17% of the net profit attributable to ordinary shareholders[88] - The largest shareholder, Nanjing New Work Investment Group, held 227,943,839 shares, representing 45.23% of the total shares before the change[135] Compliance and Risk Management - The company emphasizes quality management and compliance with the new GMP standards to ensure product safety and reliability[124] - The company has not engaged in derivative investments during the reporting period, reflecting a conservative investment strategy[70] - The company faces risks from government pricing policies and potential declines in gross margins due to competitive bidding in the pharmaceutical sector[79] Employee and Workforce Management - The company employed a total of 5,325 staff, with 2,829 in technical roles, 764 in production, and 615 in sales[159] - The remuneration policy aims to maintain market competitiveness and internal fairness, positioning overall salary levels above the industry average[160] - The company emphasizes employee training and development through various programs, including onboarding and skills training[161]

金陵药业股份有限公司 2015 年第三季度报告正文 证券代码：000919 证券简称：金陵药业 公告编号：2015-027 金陵药业股份有限公司 2015 年第三季度报告正文 1 金陵药业股份有限公司 2015 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈志龙、主管会计工作负责人李春敏及会计机构负责人(会计主管人员)汪洋声明：保证季 度报告中财务报表的真实、准确、完整。 2 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,797,208,447.07 | 3,622,217,110.96 | | 4.83% | | 归属于上市公司股东的净资产 | 2,396,832,490.58 | | 2,320,642,96 ...

Financial Performance - The company's operating revenue for the first half of 2015 was ¥1,567,871,876.59, representing a 13.48% increase compared to ¥1,381,578,780.65 in the same period last year[20]. - The net profit attributable to shareholders was ¥115,917,146.85, up 5.93% from ¥109,426,649.55 year-on-year[20]. - The net profit after deducting non-recurring gains and losses decreased by 8.93% to ¥99,755,966.02 from ¥109,541,772.48 in the previous year[20]. - The net cash flow from operating activities was ¥84,183,697.74, down 19.61% from ¥104,724,145.88 in the same period last year[20]. - The total assets at the end of the reporting period were ¥3,637,291,737.71, a slight increase of 0.42% from ¥3,622,217,110.96 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 1.42% to ¥2,353,683,813.54 from ¥2,320,642,964.82 at the end of the previous year[20]. - The basic earnings per share rose to ¥0.2300, reflecting a 5.94% increase from ¥0.2171 in the same period last year[20]. - The diluted earnings per share also increased to ¥0.2300, up 5.94% from ¥0.2171 year-on-year[20]. - The weighted average return on equity was 4.87%, slightly down from 4.94% in the previous year[20]. Revenue and Profit Breakdown - Operating profit reached CNY 185,094,700, an increase of 15.70% compared to the same period last year[33]. - Revenue from medical services reached CNY 361,095,769.86, with a gross margin of 27.04%, up 3.93% year-on-year[37]. - The gross margin for pharmaceutical production and sales was 24.47%, a decrease of 2.87% compared to the previous year[37]. - The subsidiary Nanjing Huadong Pharmaceutical Co., Ltd. reported a net profit of ¥2,433,523.44 on revenue of ¥873,080,220[52]. - The subsidiary Yunnan Jinling Plant Pharmaceutical Co., Ltd. achieved a net profit of ¥261,768.41 with revenue of ¥6,812,434.90[52]. - The subsidiary Nanjing Yitong Pharmaceutical reported revenue of approximately 43.839 million yuan, with a net profit of 22.501 million yuan[54]. - The subsidiary Nanjing Jinling Pharmacy reported revenue of approximately 73.943 million yuan, with a net profit of 1.607 million yuan[53]. - The company reported a net profit of CNY 141,598,097.57, which is an increase of 11% compared to CNY 127,586,511.12 from the previous year[118]. Cash Flow and Investments - The company’s R&D investment increased by 16.33% to CNY 14,866,823.61[33]. - The company’s investment activities generated a net cash flow of -CNY 54,255,379.36, an increase of 76.12% compared to the previous year[34]. - The total cash inflow from investment activities was CNY 622,632,220.78, while cash outflow was CNY 676,887,600.14, resulting in a net cash flow of -CNY 54,255,379.36[126]. - The company reported a cash and cash equivalents balance of CNY 624,651,217.96 at the end of the period, down from CNY 726,133,272.58 at the end of the previous period[127]. - The company incurred a financial expense of -CNY 2,123,322.25, which is an improvement compared to -CNY 8,164,736.13 in the previous year, indicating a reduction in financial costs[121]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The company implemented a cash dividend plan for 2014, distributing 1.70 yuan per 10 shares, totaling approximately 85.68 million yuan[56]. - The total number of ordinary shareholders at the end of the reporting period was 28,434[94]. - The largest shareholder, Nanjing New Industry Investment Group, holds 45.23% of the shares, totaling 227,943,800 shares[95]. - The second largest shareholder, Fuzhou Investment Management Company, holds 4.94%, totaling 24,920,000 shares[95]. - The total owner's equity at the end of the period was 504,000,000.00, with a significant portion attributed to retained earnings[140]. Corporate Governance and Compliance - The governance structure of the company has been enhanced, complying with relevant laws and regulations, with no discrepancies noted[62]. - The company has not experienced any major litigation or arbitration matters during the reporting period[63]. - The company has no penalties or rectification situations during the reporting period[87]. - There are no risks of delisting due to illegal activities during the reporting period[88]. - The company did not conduct an audit for the half-year financial report[107]. Financial Instruments and Accounting Policies - The company’s financial statements comply with the requirements of enterprise accounting standards[153]. - The company uses RMB as its accounting currency[156]. - Financial assets are classified at initial recognition into categories such as fair value through profit or loss, held-to-maturity investments, loans and receivables, and available-for-sale financial assets[167]. - The company recognizes investment income from equity interests based on fair value adjustments at the acquisition date for previously held interests[159]. - The company assesses the carrying value of financial assets at each balance sheet date, recognizing impairment losses when objective evidence indicates a decline in value[172]. Operational Activities - The company operates three hospitals, with the Suqian Hospital aiming for "three-level A" certification, achieving a business income of CNY 41,494,430.00 in the first half of 2015[31]. - The company has engaged in multiple communications with investors regarding its operational status during the reporting period[59]. - The company did not acquire any assets during the reporting period[66]. - The company sold 100% equity of Anhui Jiarun Pharmaceutical Co., Ltd. for a transaction price of 12.33 million yuan, contributing 6.80% to the net profit[67]. - There were no corporate mergers during the reporting period[68].

金陵药业股份有限公司 2015 年第一季度报告全文 金陵药业股份有限公司 2015 年第一季度报告 2015-014 2015 年 04 月 1 金陵药业股份有限公司 2015 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈志龙、主管会计工作负责人李春敏及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2015 年第一季度报告全文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 712,972,532.63 | 636,029,342.61 | 12.10% | | 归属于上市公司股东的净利润（元） | 57,2 ...

金陵药业股份有限公司 2015 年第一季度报告正文 证券代码：000919 证券简称：金陵药业 公告编号：2015-015 所有董事均已出席了审议本次季报的董事会会议。 公司负责人沈志龙、主管会计工作负责人李春敏及会计机构负责人(会计主 管人员)汪洋声明：保证季度报告中财务报表的真实、准确、完整。 2 金陵药业股份有限公司 2015 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 金陵药业股份有限公司 2015 年第一季度报告正文 1 金陵药业股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 712,972,532.63 | 636,029,342.61 | 12.10% | | 归属于上市公 ...

Financial Performance - The company's operating revenue for 2014 was CNY 2,771,942,286.51, representing a 6.38% increase compared to CNY 2,605,713,782.39 in 2013[18]. - The net profit attributable to shareholders for 2014 was CNY 197,184,453.90, a 26.49% increase from CNY 155,890,349.35 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 170,914,204.32, up 14.38% from CNY 149,420,995.06 in 2013[18]. - The basic earnings per share for 2014 was CNY 0.3912, reflecting a 26.48% increase from CNY 0.3093 in 2013[18]. - The total assets at the end of 2014 were CNY 3,622,217,110.96, a 9.62% increase from CNY 3,304,398,493.00 at the end of 2013[18]. - The net assets attributable to shareholders increased by 5.38% to CNY 2,320,642,964.82 from CNY 2,202,175,579.96 in 2013[18]. - The net cash flow from operating activities was CNY 299,891,714.98, which is a 10.58% increase compared to CNY 271,208,292.52 in the previous year[18]. - The weighted average return on equity for 2014 was 8.72%, an increase of 1.53% from 7.19% in 2013[18]. Investment and R&D - Research and development investment increased by 10.23% to CNY 40,137,604.93, indicating a commitment to innovation[27]. - Research and development expenses amounted to CNY 40,137,600, accounting for 1.45% of the total operating revenue[6]. - The company plans to invest significantly in R&D, as developing a new drug involves substantial upfront costs and lengthy approval processes, which may introduce uncertainties[65]. - The company has established provincial-level enterprise technology centers and joint laboratories with universities, enhancing its research capabilities[46]. Market and Operational Strategies - The company plans to expand its medical services through the acquisition of Anqing City Stone Chemical Hospital, which is expected to have a minor impact on overall performance[59]. - The company aims to achieve a balanced profitability level between its pharmaceutical production and medical services platforms within 3-5 years[62]. - The company plans to enhance its overall profitability by focusing on the construction of two platforms and improving the efficiency of its sales team in response to increasing market competition[62]. - The company is focusing on enhancing its digital marketing strategies, with a 25% increase in budget allocation for online advertising campaigns[138]. - The company is exploring strategic initiatives for mergers and acquisitions to bolster growth and market share[200]. Financial Stability and Risks - The company has maintained a stable main business revenue and a low debt ratio, indicating high financial stability[46]. - The company faces risks from government pricing policies and potential price adjustments for drugs included in medical insurance directories, which could create uncertainty in growth[65]. - The company has a strong credit rating and is capable of raising funds through multiple channels to meet its operational and project renovation funding needs[62]. - The company has highlighted potential industry risks and challenges in its board report, urging investors to pay attention to investment risks[12]. Shareholder and Dividend Information - The company plans to distribute a cash dividend of CNY 1.70 per 10 shares to all shareholders[2]. - The cash dividend represented 100% of the total profit distribution for the year[79]. - The company maintained compliance with its cash dividend policy, ensuring the protection of minority shareholders' rights[77]. - The total cash dividend distributed was ¥85,680,000, which accounted for 43.45% of the net profit attributable to shareholders[79]. Corporate Governance and Compliance - The company has established a robust internal control system to ensure compliance with relevant laws and regulations[84]. - The independent directors attended all board meetings and shareholder meetings, demonstrating active participation in governance[161]. - The audit committee held three meetings in 2014 to review financial reports and ensure accountability[162]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, institutions, and finance[168]. Employee and Management Information - The total number of employees at the company is 4,578, with 861 in production (18.81%) and 612 in sales (13.37%)[145]. - The company aims to maintain a competitive salary level above the industry average to attract and retain talent[150]. - The total annual compensation for 13 directors, supervisors, and senior management personnel was 6.4278 million yuan (pre-tax) during the reporting period[139]. - The compensation for senior management is determined based on performance, responsibilities, and the company's operational results[139]. Future Outlook - Future outlook indicates a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[135]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming periods[200]. - The management team has set a performance guidance of achieving a net profit margin of 15% for the upcoming fiscal year[135].

Financial Performance - Net profit attributable to shareholders increased by 32.50% to CNY 52,272,882.70 for the reporting period[7] - Operating revenue for the period was CNY 678,025,611.08, representing a 12.06% increase year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 30.68% to CNY 35,880,904.13[7] - Basic earnings per share increased by 32.44% to CNY 0.1037[7] - The weighted average return on equity improved to 2.40%, an increase of 0.58 percentage points[7] - Cash flow from operating activities for the year-to-date reached CNY 163,518,592.38, up 76.04%[7] - Net cash flow from operating activities increased by 76.04% year-on-year, primarily due to higher cash receipts from sales of goods and services[18] - Investment income rose by 81.4% compared to the same period last year, mainly due to increased investment income from financial assets measured at fair value[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,363[10] - The largest shareholder, Nanjing XG Investment Group Co., Ltd., holds 45.23% of the shares[10] - The company reported no significant changes in shareholder agreements or financing activities during the reporting period[13] Asset Changes - Total assets increased by 3.67% to CNY 3,425,657,175.89 compared to the end of the previous year[7] - Financial assets measured at fair value increased by 100.75% compared to the beginning of the year, primarily due to increased securities investments by the parent company and its subsidiary[16] - Accounts receivable rose by 33.77% compared to the beginning of the year, mainly due to the timing of drug sales payments[16] - Prepayments increased by 81.06% compared to the beginning of the year, attributed to a higher volume of purchases made on a prepayment basis[16] - Other receivables increased by 74.56% compared to the beginning of the year, largely due to significant increases in receivables from a subsidiary hospital[16] - Other current assets surged by 2391.77% compared to the beginning of the year, driven by an increase in short-term bank wealth management products held by a subsidiary[16] Liabilities and Expenses - Non-current liabilities due within one year increased by 1381.87% compared to the beginning of the year, as long-term borrowings were reclassified[17] - Financial expenses decreased by 329.85% year-on-year, attributed to reduced interest expenses and increased interest income[17] - Other payables increased by 30.46% compared to the beginning of the year, primarily due to an increase in accrued but unpaid expenses[17] Investments - The total investment in other listed companies amounted to CNY 112,784,700, with a reported loss of CNY 1,441,023[22] - The company held 500,000 shares of First Automobile Works, with an investment of CNY 5,578,500, resulting in a loss of CNY 2,568.75[22] - The investment in High德红外 resulted in a total of 650,000 shares held, with an investment of CNY 37,376,034.90 and a loss of CNY 1,854,731.43[23] - The company reported a total of CNY 46,226,786.51 in adjustments due to changes in long-term equity investment standards[27] - The total investment in 光大证券 was CNY 24,709,423.33, with a gain of CNY 1,528,281.53[23] - The investment in 保利地产 was CNY 7,775,055.25, resulting in a gain of CNY 340,384.52[23] - The company reported a total of CNY 9,375,771.50 in investments in 天壕节能, with a loss of CNY 1,214,712.63[23] Other Activities - The company did not engage in any derivative investments during the reporting period[24] - The company did not conduct any research, communication, or interview activities during the reporting period[25] - The company’s capital reserve was adjusted by CNY -5,644,214.94 due to changes in financial reporting standards[28]